N-(4-Cyclohexylphenyl)-2-hydrazino-2-oxoacetamide | 892491-74-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(4-Cyclohexylphenyl)-2-hydrazino-2-oxoacetamide
• 英文别名: N-(4-cyclohexylphenyl)-2-hydrazinyl-2-oxoacetamide
• CAS: 892491-74-6
• 化学式: C₁₄H₁₉N₃O₂
• 分子量: 261.324
• InChiKey: DFQGVONIQRROGR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  84.2
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(4-Cyclohexylphenyl)-2-hydrazino-2-oxoacetamide 、 异硫氰酸(2-氟苯)酯 在 polymer-supported carbodiimide 作用下， 生成 N-(4-cyclohexylphenyl)-5-[(2-fluorophenyl)amino]-1,3,4-oxadiazole-2-carboxamide
  参考文献：
  名称：

  Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes

  摘要：

  A novel series of DGAT-1 inhibitors was discovered from an oxadiazole amide high throughput screening (HTS) hit. Optimisation of potency and ligand lipophilicity efficiency (LLE) resulted in a carboxylic acid containing clinical candidate 53 (AZD3988), which demonstrated excellent DGAT-1 potency (0.6 nM), good pharmacokinetics and pre-clinical in vivo efficacy that could be rationalised through a PK/PD relationship. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.04.117
• 作为产物：
  描述：

  4-环己苯胺 在 吡啶 、 肼 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 生成 N-(4-Cyclohexylphenyl)-2-hydrazino-2-oxoacetamide
  参考文献：
  名称：

  Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes

  摘要：

  A novel series of DGAT-1 inhibitors was discovered from an oxadiazole amide high throughput screening (HTS) hit. Optimisation of potency and ligand lipophilicity efficiency (LLE) resulted in a carboxylic acid containing clinical candidate 53 (AZD3988), which demonstrated excellent DGAT-1 potency (0.6 nM), good pharmacokinetics and pre-clinical in vivo efficacy that could be rationalised through a PK/PD relationship. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.04.117
• 作为试剂：
  描述：

  一水合肼 、 Methyl [(4-cyclohexylphenyl)amino](oxo)acetate 在 乙醚 、 N-(4-Cyclohexylphenyl)-2-hydrazino-2-oxoacetamide 作用下， 以 乙醇 为溶剂， 反应 19.0h， 以to give the title compound (Intermediate 47, 3750 mg) as a solid的产率得到N-(4-Cyclohexylphenyl)-2-hydrazino-2-oxoacetamide
  参考文献：
  名称：

  OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS

  摘要：

  公式（I）的化合物、其盐和前药：其中，例如，R1是可选取代芳基或杂环芳基；Y是选自直接键和（取代）烷基链的连接基；R2是可选取代芳基、可选取代环烷基或可选取代杂环基团。本文描述了制备这种化合物的过程，以及它们作为DGAT抑制剂的用途，例如用于治疗肥胖症。

  公开号：

  US20100317653A1

文献信息

• Oxadiazole Derivative as Dgat Inhibitors
  申请人：Birch Martin Alan

  公开号：US20080096874A1

  公开（公告）日：2008-04-24

  Compounds of formula (I), and salts and pro-drugs thereof: Formula (I) wherein for example R 1 is optionally substituted aryl or heteroaryl; Y is a linking group selected from, for example, a direct bond, and a (substituted) alkyl chain; R 2 is an optionally substituted aryl, an optionally substituted cycloalkyl or an optionally substituted heterocyclic group; are described. Processes to make such compounds and their use as DGAT inhibitors, for example in the treatment of obesity, are also described.

  式（I）的化合物，以及其盐和前药：其中，例如R1是可选取代芳基或杂环芳基；Y是选择自直接键和（取代）烷基链等的连接基；R2是可选取代芳基、可选取代环烷基或可选取代杂环基团。还描述了制备此类化合物的方法及其作为DGAT抑制剂的用途，例如在肥胖症的治疗中。
• Oxadiazole derivative as DGAT inhibitors
  申请人：AstraZeneca AB

  公开号：US07795283B2

  公开（公告）日：2010-09-14

  Compounds of formula (I), and salts and pro-drugs thereof: Formula (I) wherein for example R1 is optionally substituted aryl or heteroaryl; Y is a linking group selected from, for example, a direct bond, and a (substituted) alkyl chain; R2 is an optionally substituted aryl, an optionally substituted cycloalkyl or an optionally substituted heterocyclic group; are described. Processes to make such compounds and their use as DGAT inhibitors, for example in the treatment of obesity, are also described.

  公式（I）的化合物，以及其盐和前药： 公式（I）其中例如R1是可选取代芳基或杂环芳基; Y是选自直接键和（取代）烷基链等连接基团; R2是可选取代芳基，可选取代环烷基或可选取代杂环基团的化合物已被描述。还描述了制备这些化合物的过程以及它们作为DGAT抑制剂的用途，例如在肥胖症的治疗中。
• US7795283B2
  申请人：——

  公开号：US7795283B2

  公开（公告）日：2010-09-14
• Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes
  作者：William McCoull、Matthew S. Addie、Alan M. Birch、Susan Birtles、Linda K. Buckett、Roger J. Butlin、Suzanne S. Bowker、Scott Boyd、Stephen Chapman、Robert D.M. Davies、Craig S. Donald、Clive P. Green、Chloe Jenner、Paul D. Kemmitt、Andrew G. Leach、Graeme C. Moody、Pablo Morentin Gutierrez、Nicholas J. Newcombe、Thorsten Nowak、Martin J. Packer、Alleyn T. Plowright、John Revill、Paul Schofield、Chris Sheldon、Steve Stokes、Andrew V. Turnbull、Steven J.Y. Wang、David P. Whalley、J. Matthew Wood

  DOI：10.1016/j.bmcl.2012.04.117

  日期：2012.6

  A novel series of DGAT-1 inhibitors was discovered from an oxadiazole amide high throughput screening (HTS) hit. Optimisation of potency and ligand lipophilicity efficiency (LLE) resulted in a carboxylic acid containing clinical candidate 53 (AZD3988), which demonstrated excellent DGAT-1 potency (0.6 nM), good pharmacokinetics and pre-clinical in vivo efficacy that could be rationalised through a PK/PD relationship. (C) 2012 Elsevier Ltd. All rights reserved.
• OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS
  申请人：BIRCH Alan Martin

  公开号：US20100317653A1

  公开（公告）日：2010-12-16

  Compounds of formula (I), and salts and pro-drugs thereof: wherein for example R 1 is optionally substituted aryl or heteroaryl; Y is a linking group selected from, for example, a direct bond, and a (substituted) alkyl chain; R 2 is an optionally substituted aryl, an optionally substituted cycloalkyl or an optionally substituted heterocyclic group; are described. Processes to make such compounds and their use as DGAT inhibitors, for example in the treatment of obesity, are also described.

  公式（I）的化合物、其盐和前药：其中，例如，R1是可选取代芳基或杂环芳基；Y是选自直接键和（取代）烷基链的连接基；R2是可选取代芳基、可选取代环烷基或可选取代杂环基团。本文描述了制备这种化合物的过程，以及它们作为DGAT抑制剂的用途，例如用于治疗肥胖症。